ALNYLAM PHARMACEUTICALS, INC. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 70.3 BRL | +4.07% |
|
+41.48% | +57.45% |
| 03:50pm | Jerome Powell did it again |  |
| 12:55pm | JPMorgan Chase Raises Price Target on Alnylam Pharmaceuticals to $248 From $160 | MT |
"Total Return" performance includes dividend payments over the period, as if they were reinvested at 100%.
End-of-day quotes
End-of-day quotes
Sector Other Biotechnology & Medical Research
| Capi. | Sales growth | Profitability | Finances | EV / Sales | P/E ratio | |
|---|---|---|---|---|---|---|
| 4.49TCr | - | |||||
| 3.78TCr | ||||||
| 3.76TCr | ||||||
| 2.74TCr | ||||||
| 2.63TCr |
